Form 4 for PTCT PTC THERAPEUTICS, INC.
Accepted 2026-05-12 17:20:06 ET · period of report 2026-05-08 · accession 0001578852-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-05-12 17:20 | 2026-05-08 | PTCT | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $46.54 | +3,540 | 106.0K | +3% | +$164.8K |
| DMT | 2026-05-12 17:20 | 2026-05-08 | PTCT | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $78.97 | -3,540 | 105.2K | -3% | -$279.6K |
| DMT | 2026-05-12 17:20 | 2026-05-08 | PTCT | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $0.00 | -3,540 | 41.5K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-08 | M | A | 2,740 | $46.54 | 107,952 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. |
| 2 | Common | Common Stock | 2026-05-08 | S | D | 840 | $78.23 | 107,112 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. (F2) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-05-08 | S | D | 1,900 | $79.31 | 105,212 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. (F3) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.03 to $79.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2026-05-08 | M | A | 800 | $46.54 | 106,012 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. |
| 5 | Common | Common Stock | 2026-05-08 | S | D | 200 | $78.00 | 105,812 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. |
| 6 | Common | Common Stock | 2026-05-08 | S | D | 600 | $79.28 | 105,212 | D | — | — | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. (F4) This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.02 to $79.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-05-08 | M | D | 2,740 | $0.00 | 42,260 | D | $46.54 · — to 2035-01-02 | 2,740 Common Stock | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. (F5) This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-05-08 | M | D | 800 | $0.00 | 41,460 | D | $46.54 · — to 2035-01-02 | 800 Common Stock | (F1) This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. (F5) This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. |